On­col­o­gists want more treat­ment op­tions for ad­vanced lung can­cer pa­tients, new sur­vey says

On­col­o­gists are en­cour­aged by the num­ber of im­munother­a­pies to treat non-small cell lung can­cer, but they still want more op­tions, es­pe­cial­ly for ad­vanced cas­es, ac­cord­ing to a new Har­ris Poll sur­vey com­mis­sioned by Re­gen­eron and the Can­cer Re­search In­sti­tute.

The over­whelm­ing ma­jor­i­ty of ad­vanced NSCLC pa­tients have used im­munother­a­py as a first-line (97%) or sec­ond-line (86%) treat­ment, ac­cord­ing to the 250 on­col­o­gists sur­veyed, but 30% of those physi­cians say there’s still room for more op­tions. Few­er than one in five on­col­o­gists rat­ed the cur­rent op­tions as “ex­cel­lent.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.